It has been about a month since the last earnings report for Nevro (NVRO). Shares have added about 0.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...

StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the medical equipment provider’s stock. Other equities ...

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos Morgan Stanley upgrades key MedTech stocks ...

Analysts say these cheap stocks have plenty of upside.

StockNews.com began coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report published on Saturday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.